当前位置:首页 >财报库 > 报告详情

费森尤斯Fresenius(FMS)2025年半年度财报「NYSE」(英文版)(63页).pdf

上传人: 1****1 编号:923196 2025-09-24 63页 723.31KB

下载:

1、H1|2025HALF-YEAR FINANCIAL REPORT At a Glance Shareholder Information Interim Group Management Report Financial Statements Financial Calendar/Contact Table of contents Fresenius|Quarterly Financial Report|1st Half and 2nd Quarter 2025 2 TABLE OF CONTENTS 20 Business segments 3 Fresenius Group figure

2、s at a glance 20 Fresenius Kabi 28 Consolidated financial statements 22 Fresenius Helios 28 Consolidated statement of income 24 Employees 29 Consolidated statement of comprehensive income 4 Shareholder information 24 Research and development 30 Consolidated statement of financial position 24 Rating

3、31 Consolidated statement of cash flows 25 Opportunities and risk report 33 Consolidated statement of changes in equity 6 Interim Group Management Report 26 Outlook 2025 37 Consolidated segment reporting first half of 2025 6 Strategy and goals 38 Consolidated segment reporting second quarter of 2025

4、 9 Healthcare industry 9 External factors 10 Results of operations,financial position,assets and liabilities 39 Notes 10 Revenue 11 Earnings 14 Reconciliation 62 Financial Calendar 15 Investments 15 Divestments 17 Cash flow 18 Asset and liability structure At a Glance Shareholder Information Interim

5、 Group Management Report Financial Statements Financial Calendar/Contact Table of contents Fresenius|Quarterly Financial Report|1st Half and 2nd Quarter 2025 3 FRESENIUS GROUP FIGURES AT A GLANCE Fresenius is a global healthcare company.Committed to life the health and wellbeing of patients is Frese

6、nius top priority.For more than 100 years,we have been combining cutting-edge technology with a focus on patients,paving the way for the therapies of the future.REVENUE AND EARNINGS in millions Q2/2025 Growth Growth in constant currency1 H1/2025 Growth Growth in constant currency1 Revenue2 5,571 3%5

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
- **公司业绩**:2025年上半年,Fresenius集团收入增长5%,达到112.02亿欧元,调整后净收入增长8%,达到4.92亿欧元。 - **股东信息**:Fresenius股票在2025财年前六个月上涨约27%,优于德国和美国的主要指数。 - **策略与目标**:Fresenius致力于通过创新医疗保健产品和服务,改善患者的生活质量,并专注于生物制药、医疗技术和护理服务。 - **业务部门**:Fresenius Kabi和Fresenius Helios是核心业务,分别实现收入增长。 - **财务状况**:净债务/EBITDA比率为3.1倍,调整后投资资本回报率为6.2%。 - **投资与剥离**:Fresenius完成了对Fresenius Vamed的剥离,并出售了Fresenius Medical Care的部分股份。
"2025上半年财报亮点" "Fresenius股价飙升,原因何在?" "Fresenius战略布局,未来展望如何?"
客服
商务合作
小程序
服务号
折叠